SPRY ARS Pharmaceuticals Inc: Total Company Value-to-Revenue Ratio

Public company logo of ars-pharma.com (SPRY)

ARS Pharmaceuticals is attracting leading biochemists through the development of the innovative drug Neffy, utilizing an ambitious startup approach and RSUs for talent retention. The change in EV/Sales demonstrates the current market valuation, while the value of 2630.10 reflects this status. The business model ensures high scalability due to the low cost of mass-producing sprays, and the commercial launch of non-throat allergy treatments is driving rapid revenue growth.

ARS Pharmaceuticals Inc - SPRY Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

ARS Pharmaceuticals Inc - analytical breakdowns and key metrics (SPRY)

- current price and projected stock value:
Initial company analysis:ars-pharma.com SPRY
Product sample of ARS Pharmaceuticals, Inc.

This ratio relates the enterprise value, including debt and subtracting cash, to total sales. It determines the market value of one dollar of revenue, excluding the impact of the debt load. By analyzing the EV-to-revenue trend, an investor assesses the asset's fundamental resilience to market shocks. For ARS Pharmaceuticals (SPRY), this indicator reflects the capitalization of Neffy's potential as a unique emergency relief tool. The metric allows for an understanding of the extent to which the market overvalues the innovativeness of this adrenaline delivery system.

Competitor analysis

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue Theravance Biopharma, Inc. (TBPH)|Company Value to Revenue AQST (Aquestive Pharma)|SCPH - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio